Improved Outcome for AML Relapse after Allogeneic Transplant with High Intensity Chemotherapy Followed By 2nd Allogeneic Stem Cell Transplant or Donor Lymphocyte Infusion; A Retrospective Analysis
Acute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (allo SCT) remains a major therapeutic challenge. While patients with longer remission after initial allo SCT are recommended to receive either 2nd allo SCT or donor lymphocyte infusion (2nd allo SCT/DLI), survival probability for patients relapsing within 6 months of SCT are dismal. We evaluated the outcomes of AML relapse after allo SCT to assess the impact of 2nd allo SCT/DLI on long term survival.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Neal Shah, Kevin Rakszawski, Myles Nickolich, W. Christopher Ehmann, Baldeep Wirk, Seema Naik, Witold Rybka, Hong Zheng, Joseph Mierski, Brooke Silar, Gina Mackey, Robert J. Greiner, Valerie Brown, David F. Claxton, Shin Mineishi, Kentaro Minagawa Tags: 133 Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Chemotherapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants